On the Up: SmithKline Beecham
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SMITHKLINE BEECHAM was back at the top of speculators' lists of likely takeover targets after an $80bn (pounds 49.4bn) battle for Warner-Lambert in the US rekindled expectations of industry consolidation.
SmithKline Beecham duly saw its shares rocket 12 per cent last week, its best five-day run since a 13 per cent gain when an HSBC analyst last month said that SmithKline's stock was cheap compared with those of other drug makers.
SmithKline Beecham, Britain's third-biggest drug maker, last year held fruitless merger talks with Glaxo Wellcome and later with American Home Products, now one of the bidders for Warner- Lambert.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments